The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

USA: A recent economic evaluation has highlighted the significant long-term health benefits of tirzepatide and semaglutide in ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

Prices would require additional discounts of 30.5 and 81.9 percent for tirzepatide and semaglutide, respectively, from the current net prices in order to reach the $100,000/QALY threshold.